Personalized approach to growth hormone treatment: Clinical use of growth prediction models

J. M. Wit, M. B. Ranke, K. Albertsson-Wikland, A. Carrascosa, R. G. Rosenfeld, S. Van Buuren, B. Kristrom, E. Schoenau, L. Audi, A. C.S. Hokken-Koelega, P. Bang, H. Jung, W. F. Blum, L. A. Silverman, P. Cohen, S. Cianfarani, C. Deal, P. E. Clayton, L. De Graaff, J. DahlgrenJ. Kleintjens, M. Roelants

Research output: Contribution to journalReview article

33 Citations (Scopus)

Abstract

The goal of growth hormone (GH) treatment in a short child is to attain a fast catch-up growth toward the target height (TH) standard deviation score (SDS), followed by a maintenance phase, a proper pubertal height gain, and an adult height close to TH. The short-term response variable of GH treatment, first-year height velocity (HV) (cm/year or change in height SDS), can either be compared with GH response charts for diagnosis, age and gender, or with predicted HV based on prediction models. Three types of prediction models have been described: the Kabi International Growth Hormone Study models, the Gothenburg models and the Cologne model. With these models, 50-80% of the variance could be explained. When used prospectively, individualized dosing reduces the variation in growth response in comparison with a fixed dose per body weight. Insulin-like growth factor-I-based dose titration also led to a decrease in the variation. It is uncertain whether adding biochemical, genetic or proteomic markers may improve the accuracy of the prediction. Prediction models may lead to a more evidence-based approach to determine the GH dose regimen and may reduce the drug costs for GH treatment. There is a need for user-friendly software programs to make prediction models easily available in the clinic.

Original languageEnglish (US)
Pages (from-to)257-270
Number of pages14
JournalHormone Research in Paediatrics
Volume79
Issue number5
DOIs
StatePublished - Jun 1 2013
Externally publishedYes

Fingerprint

Growth Hormone
Growth
Therapeutics
Drug Costs
Insulin-Like Growth Factor I
Proteomics
Molecular Biology
Software
Body Weight
Maintenance

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Wit, J. M., Ranke, M. B., Albertsson-Wikland, K., Carrascosa, A., Rosenfeld, R. G., Van Buuren, S., ... Roelants, M. (2013). Personalized approach to growth hormone treatment: Clinical use of growth prediction models. Hormone Research in Paediatrics, 79(5), 257-270. https://doi.org/10.1159/000351025
Wit, J. M. ; Ranke, M. B. ; Albertsson-Wikland, K. ; Carrascosa, A. ; Rosenfeld, R. G. ; Van Buuren, S. ; Kristrom, B. ; Schoenau, E. ; Audi, L. ; Hokken-Koelega, A. C.S. ; Bang, P. ; Jung, H. ; Blum, W. F. ; Silverman, L. A. ; Cohen, P. ; Cianfarani, S. ; Deal, C. ; Clayton, P. E. ; De Graaff, L. ; Dahlgren, J. ; Kleintjens, J. ; Roelants, M. / Personalized approach to growth hormone treatment : Clinical use of growth prediction models. In: Hormone Research in Paediatrics. 2013 ; Vol. 79, No. 5. pp. 257-270.
@article{0dcb0abdcb9a4936b49b511f34dab70e,
title = "Personalized approach to growth hormone treatment: Clinical use of growth prediction models",
abstract = "The goal of growth hormone (GH) treatment in a short child is to attain a fast catch-up growth toward the target height (TH) standard deviation score (SDS), followed by a maintenance phase, a proper pubertal height gain, and an adult height close to TH. The short-term response variable of GH treatment, first-year height velocity (HV) (cm/year or change in height SDS), can either be compared with GH response charts for diagnosis, age and gender, or with predicted HV based on prediction models. Three types of prediction models have been described: the Kabi International Growth Hormone Study models, the Gothenburg models and the Cologne model. With these models, 50-80{\%} of the variance could be explained. When used prospectively, individualized dosing reduces the variation in growth response in comparison with a fixed dose per body weight. Insulin-like growth factor-I-based dose titration also led to a decrease in the variation. It is uncertain whether adding biochemical, genetic or proteomic markers may improve the accuracy of the prediction. Prediction models may lead to a more evidence-based approach to determine the GH dose regimen and may reduce the drug costs for GH treatment. There is a need for user-friendly software programs to make prediction models easily available in the clinic.",
author = "Wit, {J. M.} and Ranke, {M. B.} and K. Albertsson-Wikland and A. Carrascosa and Rosenfeld, {R. G.} and {Van Buuren}, S. and B. Kristrom and E. Schoenau and L. Audi and Hokken-Koelega, {A. C.S.} and P. Bang and H. Jung and Blum, {W. F.} and Silverman, {L. A.} and P. Cohen and S. Cianfarani and C. Deal and Clayton, {P. E.} and {De Graaff}, L. and J. Dahlgren and J. Kleintjens and M. Roelants",
year = "2013",
month = "6",
day = "1",
doi = "10.1159/000351025",
language = "English (US)",
volume = "79",
pages = "257--270",
journal = "Hormone Research in Paediatrics",
issn = "1663-2818",
publisher = "S. Karger AG",
number = "5",

}

Wit, JM, Ranke, MB, Albertsson-Wikland, K, Carrascosa, A, Rosenfeld, RG, Van Buuren, S, Kristrom, B, Schoenau, E, Audi, L, Hokken-Koelega, ACS, Bang, P, Jung, H, Blum, WF, Silverman, LA, Cohen, P, Cianfarani, S, Deal, C, Clayton, PE, De Graaff, L, Dahlgren, J, Kleintjens, J & Roelants, M 2013, 'Personalized approach to growth hormone treatment: Clinical use of growth prediction models', Hormone Research in Paediatrics, vol. 79, no. 5, pp. 257-270. https://doi.org/10.1159/000351025

Personalized approach to growth hormone treatment : Clinical use of growth prediction models. / Wit, J. M.; Ranke, M. B.; Albertsson-Wikland, K.; Carrascosa, A.; Rosenfeld, R. G.; Van Buuren, S.; Kristrom, B.; Schoenau, E.; Audi, L.; Hokken-Koelega, A. C.S.; Bang, P.; Jung, H.; Blum, W. F.; Silverman, L. A.; Cohen, P.; Cianfarani, S.; Deal, C.; Clayton, P. E.; De Graaff, L.; Dahlgren, J.; Kleintjens, J.; Roelants, M.

In: Hormone Research in Paediatrics, Vol. 79, No. 5, 01.06.2013, p. 257-270.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Personalized approach to growth hormone treatment

T2 - Clinical use of growth prediction models

AU - Wit, J. M.

AU - Ranke, M. B.

AU - Albertsson-Wikland, K.

AU - Carrascosa, A.

AU - Rosenfeld, R. G.

AU - Van Buuren, S.

AU - Kristrom, B.

AU - Schoenau, E.

AU - Audi, L.

AU - Hokken-Koelega, A. C.S.

AU - Bang, P.

AU - Jung, H.

AU - Blum, W. F.

AU - Silverman, L. A.

AU - Cohen, P.

AU - Cianfarani, S.

AU - Deal, C.

AU - Clayton, P. E.

AU - De Graaff, L.

AU - Dahlgren, J.

AU - Kleintjens, J.

AU - Roelants, M.

PY - 2013/6/1

Y1 - 2013/6/1

N2 - The goal of growth hormone (GH) treatment in a short child is to attain a fast catch-up growth toward the target height (TH) standard deviation score (SDS), followed by a maintenance phase, a proper pubertal height gain, and an adult height close to TH. The short-term response variable of GH treatment, first-year height velocity (HV) (cm/year or change in height SDS), can either be compared with GH response charts for diagnosis, age and gender, or with predicted HV based on prediction models. Three types of prediction models have been described: the Kabi International Growth Hormone Study models, the Gothenburg models and the Cologne model. With these models, 50-80% of the variance could be explained. When used prospectively, individualized dosing reduces the variation in growth response in comparison with a fixed dose per body weight. Insulin-like growth factor-I-based dose titration also led to a decrease in the variation. It is uncertain whether adding biochemical, genetic or proteomic markers may improve the accuracy of the prediction. Prediction models may lead to a more evidence-based approach to determine the GH dose regimen and may reduce the drug costs for GH treatment. There is a need for user-friendly software programs to make prediction models easily available in the clinic.

AB - The goal of growth hormone (GH) treatment in a short child is to attain a fast catch-up growth toward the target height (TH) standard deviation score (SDS), followed by a maintenance phase, a proper pubertal height gain, and an adult height close to TH. The short-term response variable of GH treatment, first-year height velocity (HV) (cm/year or change in height SDS), can either be compared with GH response charts for diagnosis, age and gender, or with predicted HV based on prediction models. Three types of prediction models have been described: the Kabi International Growth Hormone Study models, the Gothenburg models and the Cologne model. With these models, 50-80% of the variance could be explained. When used prospectively, individualized dosing reduces the variation in growth response in comparison with a fixed dose per body weight. Insulin-like growth factor-I-based dose titration also led to a decrease in the variation. It is uncertain whether adding biochemical, genetic or proteomic markers may improve the accuracy of the prediction. Prediction models may lead to a more evidence-based approach to determine the GH dose regimen and may reduce the drug costs for GH treatment. There is a need for user-friendly software programs to make prediction models easily available in the clinic.

UR - http://www.scopus.com/inward/record.url?scp=84878374134&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878374134&partnerID=8YFLogxK

U2 - 10.1159/000351025

DO - 10.1159/000351025

M3 - Review article

C2 - 23735882

AN - SCOPUS:84878374134

VL - 79

SP - 257

EP - 270

JO - Hormone Research in Paediatrics

JF - Hormone Research in Paediatrics

SN - 1663-2818

IS - 5

ER -

Wit JM, Ranke MB, Albertsson-Wikland K, Carrascosa A, Rosenfeld RG, Van Buuren S et al. Personalized approach to growth hormone treatment: Clinical use of growth prediction models. Hormone Research in Paediatrics. 2013 Jun 1;79(5):257-270. https://doi.org/10.1159/000351025